<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206841</url>
  </required_header>
  <id_info>
    <org_study_id>NAFLD_cohort</org_study_id>
    <nct_id>NCT02206841</nct_id>
  </id_info>
  <brief_title>Establishment of NAFLD Cohort and Development of Fibrosis Markers</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for establishment of non-alcoholic fatty liver disease patients cohort
      to development of markers to predict histologic progression of liver fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Acoustic radiation force impulse elastography

        -  Liver tissue (frozen tissue, paraffin block)

        -  Whole blood, Serum

        -  Fat amount ratio CT (Visceral adipose tissue, Subcutaneous adipose tissue amount)

        -  Body composition analyzer (InBody scale):Total fat/muscle mass and appendicular skeletal
           muscle mass
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>histologic steatosis and fibrosis grade</measure>
    <time_frame>baseline</time_frame>
    <description>We will evaluate fibrosis using laboratory examination, radiologic evaluation and liver tissue pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of markers for hepatic fibrosis progression</measure>
    <time_frame>baseline and every 6 months (up to 1year)</time_frame>
    <description>We will analysis and development fibrosis markers by obtained blood sample and liver tissue,</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Fibrosis of Liver</condition>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
    <description>Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, and metabolomics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARFI</intervention_name>
    <description>Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SWE</intervention_name>
    <description>Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transient elastography</intervention_name>
    <description>Transient elastography will be performed for evaluate fibrosis of liver.</description>
    <arm_group_label>NAFLD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Obtained blood samples will be stored by serum and plasma for future analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-alcoholic fatty liver disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed fatty liver disease

          -  Patients with radiologically confirmed fatty liver disease

        Exclusion Criteria:

          -  History of significant alcohol consumption

          -  Viral hepatitis

          -  Autoimmune hepatitis

          -  Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)

          -  Hepatotoxic medication (e.g. amiodarone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Kim, MD,PhD</last_name>
    <phone>8228702233</phone>
    <email>drwon1@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saekyung Joo, MD</last_name>
    <phone>821089619285</phone>
    <email>joo.sammy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Kim, MD, PhD</last_name>
      <phone>8228702233</phone>
      <email>drwon1@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, Kim W. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1111/jgh.14056. [Epub ahead of print]</citation>
    <PMID>29193269</PMID>
  </results_reference>
  <results_reference>
    <citation>Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, Chang MS, Kim JH, Lee J, Jeong WI, Kim W. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2018 Apr;38(4):695-705. doi: 10.1111/liv.13587. Epub 2017 Sep 30.</citation>
    <PMID>28898507</PMID>
  </results_reference>
  <results_reference>
    <citation>Joo SK, Kim W, Kim D, Kim JH, Oh S, Lee KL, Chang MS, Jung YJ, So YH, Lee MS, Bae JM, Kim BG. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int. 2018 Feb;38(2):331-341. doi: 10.1111/liv.13549. Epub 2017 Sep 5.</citation>
    <PMID>28796410</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A. Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis. Clin Gastroenterol Hepatol. 2018 Jan;16(1):123-131.e1. doi: 10.1016/j.cgh.2017.08.014. Epub 2017 Aug 18.</citation>
    <PMID>28823829</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim JY, Park KJ, Hwang JY, Kim GH, Lee D, Lee YJ, Song EH, Yoo MG, Kim BJ, Suh YH, Roh GS, Gao B, Kim W, Kim WH. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. J Hepatol. 2017 Aug;67(2):349-359. doi: 10.1016/j.jhep.2017.03.023. Epub 2017 Mar 30.</citation>
    <PMID>28365312</PMID>
  </results_reference>
  <results_reference>
    <citation>Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017 Jan;66(1):123-131. doi: 10.1016/j.jhep.2016.08.019. Epub 2016 Sep 4.</citation>
    <PMID>27599824</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee MS, Bae JM, Joo SK, Woo H, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One. 2017 Nov 27;12(11):e0188321. doi: 10.1371/journal.pone.0188321. eCollection 2017.</citation>
    <PMID>29176844</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Won Kim</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>fibrosis</keyword>
  <keyword>markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

